Myocardial Viability and Survival in Ischemic Left Ventricular DysfunctionRobert O. Bonow, Julio A. Panza, Robert E. Michler et al.|New England Journal of Medicine|2011Cited by 877
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumFrank Dieterle, J. Eric McDuffie, Frank D. Sistare et al.|Nature Biotechnology|2010Cited by 406
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertensionDiana Bonderman, Iréne Lang, Johannes Jakowitsch et al.|Thrombosis and Haemostasis|2005Cited by 296
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertensionDiana Bonderman, Iréne Lang, Peter L. Turecek et al.|Thrombosis and Haemostasis|2003Cited by 254
Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?Nalini M. Rajamannan, Natesa G. Pandian, Francesco Antonini‐Canterin et al.|PubMed|2009Cited by 22